A Phase 2 interventional study of PF-06835375 in Primary Immune Thrombocytopenia, sponsored by Pfizer. Terminated at 24 sites in 7 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
The study terminated due to a business decision. The decision to terminate the trial was not based on any safety concerns.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Australia — 6 open to participants now, 9 under way, 4 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Australia.
Among the 29 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Australia, this one is the 18th largest by enrollment of the 28 interventional ones that give a count, is the only one that started in 2022, is one of 7 in phase 2, and was the 19th registered.
505 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 160 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →6 of the 29 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Australia are open now. Recruiting first, the newest first:
Incyte Corporation · Sites in Australia, United States, France and 4 more countries
Ages 18+
Takeda · Sites in Australia, United States, Bulgaria and 12 more countries
Ages 18+
Lakefront Biotherapeutics West LLC · Sites in Australia, United States
Ages 18–75
Takeda · Sites in Australia, United States, Bulgaria and 15 more countries
Ages 18+
Chugai Pharmaceutical · Sites in Australia, United States, Austria and 17 more countries
Ages 18–85
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 9 · Phase 3 14
First in 2006; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 61 is close to the median of 58 across 378 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 76 across the 28 interventional studies, 500 across the 1 observational. Of the 17 that completed or were terminated, 13 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 29 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,338 studies on the registry; 147 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 393 (65%) have results posted.
Pfizer has 2 studies filed under Purpura, Thrombocytopenic, Idiopathic — fewer than ten, so there is no comparison to draw.
4 of the studies in Purpura, Thrombocytopenic, Idiopathic with a site in Australia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04812925Phase 3argenxA Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia | 2027-10 |
| NCT07083960Lakefront Biotherapeutics West LLCOM336 in Autoimmune Cytopenias | 2026-12 |
| NCT06371417Chugai PharmaceuticalPhase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) | 2027-03-31 |
| NCT07104565Incyte CorporationStudy to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders | 2027-09-23 |
Add all 4 to your calendar (.ics) → With an account.
Among the 29 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, open-label, multicenter, multiple subcutaneous injection, safety and efficacy study of PF-06835375 in adult participants with primary immune thrombocytopenia (ITP). This study will focus on participants with persistent (>3 months and ≤12 months), or chronic (>12 months) ITP
This study is designed to elucidate the effects of PF-06835375 on platelet counts in participants with moderate to severe primary ITP. Based on the experience with other B-cells depleting agents, it is expected that the platelet counts will increase following a standard treatment. Each participant in cohort 1 received 1 subcutaneous injection of dose 1 every month for 3 months during the 12-week treatment period. Each participant in cohorts 2, 3, or 4 (will) receive(d) subcutaneous injection(s) of dose 2, 3, or 4 every month for 4 months during the 16-week treatment period. This should provide sufficient levels of exposure and depletion of CXCR5 positive cells to sustain the effects of PF-06835375 during the treatment period. Additional depletion of Tfh cells may provide sustained increase in platelet count following the last treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
subcutaneous injection once monthly for 3 months
Biological: PF-06835375
subcutaneous injection once monthly for 4 months
Biological: PF-06835375
subcutaneous injection once monthly for 4 months
Biological: PF-06835375
subcutaneous injections once monthly for 4 months
Biological: PF-06835375
CXCR5 inhibitor
Proportion of participants with change from baseline of platelet counts
To evaluate absolute value of platelet count of treated participants
Time frame: baseline through 12 and 16 weeks
proportion of participants with modified overall response (mOR)
To evaluate the modified overall response of platelet count of treated participants
Time frame: baseline through 12 and 16 weeks
proportion of participants with complete response (CR)
To evaluate the complete response of platelet count of treated participants
Time frame: baseline through 12 and 16 weeks
Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)
Time frame: baseline through end of study (Week 20 for cohort 1 and Week 24 for cohorts 2 and 3)
Proportion of participants with change from baseline of platelet counts
Time frame: baseline to Week 20 and Week 24
Proportion of participants with change from baseline of circulating B cells
Time frame: baseline to Week 20 and Week 24
Proportion of participants with change from baseline of circulating cTfh cells
Time frame: baseline to Week 20 and Week 24
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Feb 2022 to primary completion in Sep 2026, 55 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Aug 2028 → Sep 2026 and completion Aug 2028 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
The study terminated due to a business decision. The decision to terminate the trial was not based on any safety concerns.
The study terminated due to a business decision. The decision to terminate the trial was not based on any safety concerns.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Purpura, Thrombocytopenic, Idiopathic →